argenx SE
argenx SE
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date16 apr 2024 - 07:10
Statutory nameargenx SE
Titleargenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Previous result
Next result
Related downloads
202404160000000003_argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease.pdf(opens in a new window)
Date last update: 17 April 2024
Disclaimer
arGEN-X SE published this content on
16 April 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
17 April 2024 01:09:01 UTC.